Mydecine Innovations Group Inc. Fundamental Analysis
Mydecine Innovations Group Inc. (MYCOF) shows weak financial fundamentals with a PE ratio of 27.69, profit margin of 0.00%, and ROE of -14.15%. The company generates N/A in annual revenue with weak year-over-year growth of 0.00%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 10.1/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze MYCOF's fundamental strength across five key dimensions:
Efficiency Score
ExcellentMYCOF demonstrates superior asset utilization.
Valuation Score
ModerateMYCOF shows balanced valuation metrics.
Growth Score
ModerateMYCOF shows steady but slowing expansion.
Financial Health Score
ModerateMYCOF shows balanced financial health with some risks.
Profitability Score
WeakMYCOF struggles to sustain strong margins.
Key Financial Metrics
Is MYCOF Expensive or Cheap?
P/E Ratio
MYCOF trades at 27.69 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, MYCOF's PEG of 0.00 indicates potential undervaluation.
Price to Book
The market values Mydecine Innovations Group Inc. at -19.65 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 55.41 times EBITDA. This signals the market has high growth expectations.
How Well Does MYCOF Make Money?
Net Profit Margin
For every $100 in sales, Mydecine Innovations Group Inc. keeps $0.00 as profit after all expenses.
Operating Margin
Core operations generate 0.00 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $-14.15 in profit for every $100 of shareholder equity.
ROA
Mydecine Innovations Group Inc. generates $77.91 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
FCF Per Share
Each share generates $-0.02 in free cash annually.
FCF Yield
MYCOF converts -0.21% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
27.69
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.00
vs 25 benchmark
P/B Ratio
Price to book value ratio
-19.65
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.00
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
-0.19
vs 25 benchmark
Current Ratio
Current assets to current liabilities
0.48
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
-0.14
vs 25 benchmark
ROA
Return on assets percentage
0.78
vs 25 benchmark
ROCE
Return on capital employed
0.22
vs 25 benchmark
How MYCOF Stacks Against Its Sector Peers
| Metric | MYCOF Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 27.69 | 29.20 | Neutral |
| ROE | -14.15% | 729.00% | Weak |
| Net Margin | 0.00% | -52856.00% (disorted) | Weak |
| Debt/Equity | -0.19 | 0.49 | Strong (Low Leverage) |
| Current Ratio | 0.48 | 4.43 | Weak Liquidity |
| ROA | 77.91% | -20711.00% (disorted) | Strong |
MYCOF outperforms its industry in 2 out of 6 key metrics, particularly excelling in ROA, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Mydecine Innovations Group Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
-100.00%
Industry Style: Defensive, Growth, Innovation
DecliningEPS CAGR
99.33%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
99.98%
Industry Style: Defensive, Growth, Innovation
High Growth